Supplemental Digital Content 2 References of reviews included in the systematic review
x1.
Berger MM, Chiolero RL: Antioxidant supplementation in sepsis and systemic inflammatory response
syndrome. Crit Care Med 2007; 35:S584-590
x2.
Beutler B, Grau GE: Tumor necrosis factor in the pathogenesis of infectious diseases. Crit Care Med
1993;21:S423-435
x3.
Biesalski HK, McGregor GP: Antioxidant therapy in critical care-is the microcirculation the primary target?
Crit Care Med 2007; 35:S577-583
x4.
Bodmer M, Fournel MA, Hinshaw LB, et al: Preclinical review of anti-tumor necrosis factor monoclonal
antibodies. Crit Care Med 1993; 21:S441-446
x5.
Bone RC: Inhibitors of complement and neutrophils: a critical evaluation of their role in the treatment of
sepsis. Crit Care Med 1992; 20:891-898
x6.
Bone RC: Phospholipids and their inhibitors: a critical evaluation of their role in the treatment of sepsis.
Crit Care Med 1992; 20:884-890
x7.
Boyer A, Chadda K, Salah A, et al: Glucocorticoid treatment in patients with septic shock: effects on
vasopressor use and mortality. Int J Clin Pharmacol Ther
2006; 44:309-318
x8.
Bozzo J. rNAPc2: Anticoagulant TF-FVIIa complex inhibitor. Drugs of the Future 2006; 31:28-33
x9.
Christman JW, Holden EP, Blackwell TS, et al: Strategies for blocking the systemic effects of cytokines in
the sepsis syndrome. Crit Care Med 1995; 23:955-963
x10.
Cornet AD, Smit EG, Beishuizen A, et al: The role of heparin and allied compounds in the treatment of
sepsis. Thromb Haemost 2007; 98:579-586
x11.
De Vriese AS, Bourgeois M: Pharmacologic treatment of acute renal failure in sepsis. Curr Opin Crit Care
2003; 9:474-480
x12.
Farand P, Hamel M, Lauzier F, et al: Review article: organ perfusion/permeability-related effects of
norepinephrine and vasopressin in sepsis. Can J Anaesth 2006; 53:934-946
x13.
Feihl F, Waeber B, Liaudet L, et al: Is nitric oxide overproduction the target of choice for the management
of septic shock? Pharmacol Ther 2001; 91:179-213
x14.
Fink MP: Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to
lipopolysaccharide. Crit Care Med 1993; 21:S32-39
x15.
Fischer U, Schulze-Osthoff K: Pharmacological modulation of caspase activation. Current Medicinal
Chemistry Anti-inflammatory & anti-allergy agents 2005; 4:407-419
x16.
Fourrier F: Therapeutic applications of antithrombin concentrates in systemic inflammatory disorders. Blood
Coagul Fibrinolysis 1998; 9:S39-45
x17.
Giroir BP: Mediators of septic shock: new approaches for interrupting the endogenous inflammatory
cascade. Crit Care Med 1993; 21:780-789
x18.
Gluck T, Opal SM: Advances in sepsis therapy. Drugs 2004; 64:837-859
x19.
Gonzalez-Rey E, Delgado M: Cortistatin as a potential multistep therapeutic agent for inflammatory
disorders. Drug News & Perspectives 2006; 19:393-399
x20.
Goode HF, Webster NR: Free radicals and antioxidants in sepsis. Crit Care Med 1993; 21:1770-1776
x21.
Harkema JM, Chaudry IH: Magnesium-adenosine triphosphate in the treatment of shock, ischemia, and
sepsis. Crit Care Med 1992; 20:263-275
x22.
Hedner U, Erhardtsen E: Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI.
Ann Med 2000; 32:68-72
x23.
Henderson A, Hayes P: Acetylcysteine as a cytoprotective antioxidant in patients with severe sepsis:
potential new use for an old drug. Ann Pharmacother 1994; 28:1086-1088
x24.
Hofstra JJ, Juffermans NP, Schultz MJ, et al: Pulmonary coagulopathy as a new target in lung injury--a
review of available pre-clinical models. Current Medicinal Chemistry 2008; 15:588-595
x25.
Honore PM, Joannes-Boyau O, Gressens B: Blood and plasma treatments: high-volume hemofiltration--a
global view. Contrib Nephrol 2007; 156:371-386
x26.
Honore PM, Joannes-Boyau O, Merson L, et al: The big bang of hemofiltration: the beginning of a new era
in the third millennium for extra-corporeal blood purification. Int J Artif Organs 2006; 29:649-659
x27.
Hurley JC: Antibiotic-induced release of endotoxin. A therapeutic paradox. Drug Saf 1995; 12:183-195
x28.
Lamontagne F, Meade M, Ondiveeran HK, et al: Nitric oxide donors in sepsis: a systematic review of
clinical and in vivo preclinical data. Shock 2008; 30:653-659
x29.
Lange M, Morelli A, Westphal M: Inhibition of potassium channels in critical illness. Curr Opin Anaesth
2008; 21:105-110
x30.
Lorente JA, Marshall JC: Neutralization of tumor necrosis factor in preclinical models of sepsis. Shock
2005; 24:107-119
x31.
Marshall JC: The effects of granulocyte colony-stimulating factor in preclinical models of infection and
acute inflammation. Shock 2005; 24:120-129
x32.
Matson J, Lee P: Evolving concepts of therapy for sepsis and septic shock and the use of hyperpermeable
membranes. Curr Opin Crit Care 2000; 6:431-436
x33.
Maynor L, Brophy DF: Risk of infection with intravenous iron therapy. Ann Pharmacother 2007; 41:14761480
x34.
Moldawer LL: Biology of proinflammatory cytokines and their antagonists. Crit Care Med 1994; 22:S3-7
x35.
Murphy FJ, Hayes I, Cotter TG: Targeting inflammatory diseases via apoptotic mechanisms. Curr Opin
Pharmacol 2003; 3:412-419
x36.
Natanson C, Hoffman WD, Suffredini AF, et al: Selected treatment strategies for septic shock based on
proposed mechanisms of pathogenesis. Ann Intern Med 1994; 120:771-783
x37.
O'Callaghan A, Redmond HP: Treatment of sepsis: current status of clinical immunotherapy. J R Coll Surg
Edinb 2006; 4:355-361
x38.
Orlicek SL: Cytokine inhibitors for sepsis and septic shock. Seminars in Pediatric Infectious Diseases 2001;
12:24-29
x39.
Parrillo JE, Parker MM, Natanson C, et al: Septic shock in humans. Advances in the understanding of
pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113:227-242
x40.
Schmidt H, Martindale R: The gastrointestinal tract in critical illness: nutritional implications. Current
Opinion in Clinical Nutrition & Metabolic Care 2003; 6:587-591
x41.
Zardi EM, Zardi DM, Dobrina A, et al: Prostacyclin in sepsis: a systematic review. Prostaglandins & Other
Lipid Mediators 2007; 83:1-24
x42.
Zhou X, Schmidtke P, Zepp F, et al: Boosting interleukin-10 production: therapeutic effects and
mechanisms. Current Drug Targets - Immune Endocrine & Metabolic Disorders 2005; 5:465-475
x43.
Suffredini AF : Current prospects for the treatment of clinical sepsis. Crit Care Med 1994; 22:S12-18
x44.
Terblanche M, Almog Y, Rosenson RS, et al: Statins and sepsis: multiple modifications at multiple levels.
Lancet Infectious Diseases 2007; 7:358-368
x45.
Timsit JF: Scheduled replacement of central venous catheters is not necessary. Infect Control Hosp
Epidemiol 2000; 21:371-374